Patients' characteristics according to MDR1 polymorphisms
| Genotype . | Trough imatinib plasma levels, ng/mL . | P* . | Age . | P . | Sokal score . | P . | Sex, no. (%) . | P . | Sokal risk group, no. (%) . | P . | Interferon before imatinib‖, no. (%) . | P . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of patients . | Mean . | (SD)† . | No. of patients . | Mean . | (SD)† . | No. of patients . | Mean . | (SD)† . | Male . | Female . | Less than 0.8 . | 0.8 to 1.2 . | More than 1.2 . | Yes . | No . | |||||||
| C1236T | .64 | .66 | .75 | .13 | .79§ | .07 | ||||||||||||||||
| CC | 26 | 992.4 | (762.8) | 27 | 53.07 | (14.62) | 25 | 0.88 | (0.24) | 20(37.7) | 7(21.9) | 12(30) | 8(42.5) | 5(27.5) | 11(23.4) | 16(42.1) | ||||||
| CT | 38 | 1087.3 | (548.9) | 38 | 53.24 | (15.50) | 34 | 0.92 | (0.37) | 24(45.3) | 14(43.8) | 17(32) | 11(44) | 6(24) | 21(44.7) | 17(44.7) | ||||||
| TT | 20 | 1157.8 | (431.6) | 20 | 49.80 | (11.53) | 19 | 0.86 | (0.22) | 9(17) | 11(34.4) | 11(38.5) | 6(46.2) | 2(15.4) | 15(31.9) | 5(13.2) | ||||||
| G2677T/A | .84 | .79 | .90 | .9§ | .95§ | .05§ | ||||||||||||||||
| GG | 29 | 1000.9 | (707.9) | 30 | 52.53 | (15.37) | 28 | 0.88 | (0.28) | 20(38.5) | 10(31.3) | 15(35.7) | 7(33.3) | 6(50.0) | 11(24.4) | 19(48.7) | ||||||
| GT | 34 | 1111.1 | (524.6) | 34 | 51.91 | (14.30) | 28 | 0.87 | (0.32) | 21(40.4) | 13(40.6) | 16(38.1) | 8(38.1) | 4(33.3) | 20(44.4) | 14(35.9) | ||||||
| TT | 16 | 1091.1 | (429.6) | 16 | 48.19 | (12.29) | 15 | 0.85 | (0.24) | 7(13.5) | 9(28.1) | 9(21.4) | 4(19) | 2(16.7) | 12(26.7) | 4(10.3) | ||||||
| Others | 4 | 907.3 | (722.7) | 4 | 50.00 | (19.41) | 4 | 0.77 | (0.16) | 4(7.7) | 0(0.0) | 2(4.8) | 2(9.5) | 0(0.0) | 2(4.4) | 2(5.1) | ||||||
| C3435T | .22‡ | .48 | .73 | .24 | .50§ | .36 | ||||||||||||||||
| CC | 16 | 1031.4 | (915.9) | 17 | 48.06 | (16.87) | 16 | 0.83 | (0.28) | 13(22.8) | 4(12.1) | 10(23.8) | 2(7.7) | 4(30.8) | 7(14.6) | 10(23.8) | ||||||
| CT | 46 | 1104.0 | (487.5) | 46 | 52.15 | (14.98) | 40 | 0.89 | (0.30) | 30(52.6) | 16(48.5) | 21(50.0) | 13(50) | 6(46.2) | 24(50) | 22(52.4) | ||||||
| TT | 27 | 1064.4 | (498.1) | 27 | 53.44 | (12.31) | 25 | 0.91 | (0.31) | 14(24.6) | 13(39.4) | 11(26.2) | 11(42.3) | 9(23.1) | 17(35.4) | 10(23.8) | ||||||
| Genotype . | Trough imatinib plasma levels, ng/mL . | P* . | Age . | P . | Sokal score . | P . | Sex, no. (%) . | P . | Sokal risk group, no. (%) . | P . | Interferon before imatinib‖, no. (%) . | P . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of patients . | Mean . | (SD)† . | No. of patients . | Mean . | (SD)† . | No. of patients . | Mean . | (SD)† . | Male . | Female . | Less than 0.8 . | 0.8 to 1.2 . | More than 1.2 . | Yes . | No . | |||||||
| C1236T | .64 | .66 | .75 | .13 | .79§ | .07 | ||||||||||||||||
| CC | 26 | 992.4 | (762.8) | 27 | 53.07 | (14.62) | 25 | 0.88 | (0.24) | 20(37.7) | 7(21.9) | 12(30) | 8(42.5) | 5(27.5) | 11(23.4) | 16(42.1) | ||||||
| CT | 38 | 1087.3 | (548.9) | 38 | 53.24 | (15.50) | 34 | 0.92 | (0.37) | 24(45.3) | 14(43.8) | 17(32) | 11(44) | 6(24) | 21(44.7) | 17(44.7) | ||||||
| TT | 20 | 1157.8 | (431.6) | 20 | 49.80 | (11.53) | 19 | 0.86 | (0.22) | 9(17) | 11(34.4) | 11(38.5) | 6(46.2) | 2(15.4) | 15(31.9) | 5(13.2) | ||||||
| G2677T/A | .84 | .79 | .90 | .9§ | .95§ | .05§ | ||||||||||||||||
| GG | 29 | 1000.9 | (707.9) | 30 | 52.53 | (15.37) | 28 | 0.88 | (0.28) | 20(38.5) | 10(31.3) | 15(35.7) | 7(33.3) | 6(50.0) | 11(24.4) | 19(48.7) | ||||||
| GT | 34 | 1111.1 | (524.6) | 34 | 51.91 | (14.30) | 28 | 0.87 | (0.32) | 21(40.4) | 13(40.6) | 16(38.1) | 8(38.1) | 4(33.3) | 20(44.4) | 14(35.9) | ||||||
| TT | 16 | 1091.1 | (429.6) | 16 | 48.19 | (12.29) | 15 | 0.85 | (0.24) | 7(13.5) | 9(28.1) | 9(21.4) | 4(19) | 2(16.7) | 12(26.7) | 4(10.3) | ||||||
| Others | 4 | 907.3 | (722.7) | 4 | 50.00 | (19.41) | 4 | 0.77 | (0.16) | 4(7.7) | 0(0.0) | 2(4.8) | 2(9.5) | 0(0.0) | 2(4.4) | 2(5.1) | ||||||
| C3435T | .22‡ | .48 | .73 | .24 | .50§ | .36 | ||||||||||||||||
| CC | 16 | 1031.4 | (915.9) | 17 | 48.06 | (16.87) | 16 | 0.83 | (0.28) | 13(22.8) | 4(12.1) | 10(23.8) | 2(7.7) | 4(30.8) | 7(14.6) | 10(23.8) | ||||||
| CT | 46 | 1104.0 | (487.5) | 46 | 52.15 | (14.98) | 40 | 0.89 | (0.30) | 30(52.6) | 16(48.5) | 21(50.0) | 13(50) | 6(46.2) | 24(50) | 22(52.4) | ||||||
| TT | 27 | 1064.4 | (498.1) | 27 | 53.44 | (12.31) | 25 | 0.91 | (0.31) | 14(24.6) | 13(39.4) | 11(26.2) | 11(42.3) | 9(23.1) | 17(35.4) | 10(23.8) | ||||||
P value was assessed using one-way ANOVA test for quantitative variables and the χ2 test for qualitative variables.
Data are mean (± SD) values for quantitative features. For qualitative features, data are numbers of patients and percentages in parentheses.
P value was assessed using a Kruskal-Wallis test because of the nonhomogeneity of variance among the 3 genotype groups.
P value calculated after Yates correction and/or gathering classes.
Two patients were also treated by nilotinib after imatinib failure.